Weiyun Ai, MD, PhD
Professor
Medicine
School of Medicine

I am a medical oncologist specializing in hematologic malignancy, with a particular emphasis on Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, and skin lymphomas. I have conducted numerous clinical trials in each of these areas. My laboratory research focuses on developing patient-derived murine models for T cell lymphomas, as well as conducting pre-clinical studies of novel agents.

Physician Biography Dr. Ai specializes in the research and treatment of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, cutaneous lymphoma and bone marrow transplantation. She cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center and Department of Dermatology. She serves as a co-director of the UCSF Cutaneous Lymphoma Program. Dr. Ai graduated top of her class from Beijing University in cell biology and genetics. She earned a Ph.D. in microbiology and immunology, as well as her M.D. degree from Stanford University School of Medicine. After a residency in medicine at UCSF and an oncology fellowship at Stanford University, Dr. Ai joined the faculty at UCSF in 2007. She serves on both the Hodgkin’s lymphoma and T cell lymphoma committees, as well as the International Program of the National Comprehensive Cancer Care Network (NCCN). Dr. Ai’s research focuses on novel approaches to lymphoma treatment, especially targeted agents for T cell lymphomas. She has published widely in medical and scientific journals.

• Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.
  European journal of nuclear medicine and molecular imaging 2023 Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB
• The relationship between serum lipid and sudden sensorineural hearing loss.
  Acta oto-laryngologica 2023 Huang J, Xu Y, Li L, Ai W
• Prognostic Relevance of Dominant Blood T-Cell Clones in Early Mycosis Fungoides-Reply.
  JAMA dermatology 2023 Charli-Joseph Y, Pincus LB, Ai WZ
• Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
  Blood advances 2022 Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF
• Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
  Blood 2022 Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, …
• Association of a Dominant T-Cell Clone in Peripheral Blood With Time to Systemic Treatment in Patients With Stage IB Mycosis Fungoides.
  JAMA dermatology 2022 Raychaudhuri S, Charli-Joseph Y, Huang CY, Mintz MA, Pincus LB, Ai WZ
• Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
  Leukemia & lymphoma 2022 Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, Chu R, Andreadis C, Kaplan L, Abdulhaq H, Fakhri B
• Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
  Blood advances 2022 Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ
• NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N…
• Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma.
  Journal of geriatric oncology 2022 Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL
• T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, …
• Dietary Plant Polyphenols as the Potential Drugs in Neurodegenerative Diseases: Current Evidence, Advances, and Opportunities.
  Oxidative medicine and cellular longevity 2022 Yan L, Guo MS, Zhang Y, Yu L, Wu JM, Tang Y, Ai W, Zhu FD, Law BY, Chen Q, Yu CL, Wong VK, Li H, Li M, Zhou XG, Qin DL, Wu AG
• Polygala saponins inhibit NLRP3 inflammasome-mediated neuroinflammation via SHP-2-Mediated mitophagy.
  Free radical biology & medicine 2021 Qiu WQ, Ai W, Zhu FD, Zhang Y, Guo MS, Law BY, Wu JM, Wong VK, Tang Y, Yu L, Chen Q, Yu CL, Liu J, Qin DL, Zhou XG, Wu AG
• Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
  The AAPS journal 2021 Hess B, Townsend W, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J
• Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
  Leukemia & lymphoma 2021 Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A…
• The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
  Clinical lymphoma, myeloma & leukemia 2021 Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M
• Current and emerging treatment options in primary mediastinal B-cell lymphoma.
  Therapeutic advances in hematology 2021 Fakhri B, Ai W
• Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
  The Lancet. Oncology 2021 Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C
• High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021 Huang LW, Sun D, Link TM, Lang T, Ai W, Kaplan LD, Steinman MA, Andreadis C
• A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.
  Clinical lymphoma, myeloma & leukemia 2021 Kennedy VE, Ruiz-Cordero R, Jangam D, Wen KW, Dunavin N, Ohgami RS, Bhargava P, Ai W, Fakhri B
• Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort.
  JAMA dermatology 2021 Charli-Joseph Y, Kashani-Sabet M, McCalmont TH, Kornak J, Allen I, Ai WZ, LeBoit PE, Pincus LB
• Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
  Clinical lymphoma, myeloma & leukemia 2020 Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB
• Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
  Clinical lymphoma, myeloma & leukemia 2020 Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB
• NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA…
• Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.
  Journal of geriatric oncology 2020 Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL
• Lychee seed polyphenol inhibits Aβ-induced activation of NLRP3 inflammasome via the LRP1/AMPK mediated autophagy induction.
  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Qiu WQ, Pan R, Tang Y, Zhou XG, Wu JM, Yu L, Law BY, Ai W, Yu CL, Qin DL, Wu AG
• Design of a closed-loop gastric pacemaker for modulating dysrhythmic conduction patterns via extracellular potentials.
  Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2020 Wang L, Malik A, Roop PS, Cheng LK, Paskaranandavadivel N, Ai W
• Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
  The Journal of investigative dermatology 2020 Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ
• Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski…
• NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, …
• United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.
  Journal of the American Academy of Dermatology 2020 Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ
• Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series.
  Clinical lymphoma, myeloma & leukemia 2019 Kambhampati S, Gray L, Fakhri B, Lo M, Vu K, Arora S, Kaplan L, Ai WZ, Andreadis C
• Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ
• Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL
• Update on the Treatment of Anaplastic Large Cell Lymphoma.
  Current hematologic malignancy reports 2018 Vu K, Ai W
• NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB…
• NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, …
• Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston …
• Remission of subcutaneous panniculitis-like T-cell lymphoma in a pregnant woman after treatment with oral corticosteroids as monotherapy.
  JAAD case reports 2017 West ES, Shinkai K, Ai WZ, Pincus LB
• Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, …
• Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC
• Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.
  Leukemia & lymphoma 2016 Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C
• Hodgkin lymphoma, version 2.2015.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N,…
• A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
  Clinical lymphoma, myeloma & leukemia 2015 Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG
• Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes.
  Oncogenesis 2014 Shi Y, Ou L, Han S, Li M, Pena MM, Pena EA, Liu C, Nagarkatti M, Fan D, Ai W
• Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
  Bone marrow transplantation 2014 Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, …
• Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
  JAMA dermatology 2014 Ai WZ, Keegan TH, Press DJ, Yang J, Pincus LB, Kim YH, Chang ET
• Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
  Journal of geriatric oncology 2014 Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL
• Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, …
• Paraneoplastic acanthosis nigricans paralleling disease course in a patient with mycosis fungoides.
  European journal of dermatology : EJD 2013 Charli-Joseph Y, Chong K, Ai WZ, Leboit PE, Pincus LB
• MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
  Blood 2013 Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, …
• Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
  Blood 2013 Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri …
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
  Blood 2013 Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, …
• CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
  Blood 2013 Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van …
• Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
  Blood 2012 Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai …
• Successful idiotypic vaccination following stem cell allotransplant in lymphoma.
  Leukemia & lymphoma 2012 de Cerio AL, Inogés S, Ai WZ, Villanueva H, Pastor F, Soldevilla MM, Soria E, Bendandi M
• Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
  Haematologica 2012 Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X,…
• Low incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China.
  Leukemia & lymphoma 2012 Pan Y, Meng B, Zhang H, Cao W, Wang H, Bi C, Liu F, Sun B, Hao X, Ai WZ, Fu K
• Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, …
• Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
  Leukemia 2012 Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill …
• Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
  Journal of cutaneous pathology 2012 Cho RJ, McCalmont TH, Ai WZ, Fox LP, Treseler P, Pincus LB
• Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study.
  British journal of haematology 2011 Ai WZ, Chang ET, Fish K, Fu K, Weisenburger DD, Keegan TH
• In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.
  Blood 2011 Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R
• Acneiform presentation of primary cutaneous follicle center lymphoma.
  Journal of the American Academy of Dermatology 2011 Soon CWM, Pincus LB, Ai WZ, McCalmont TH
• Hodgkin lymphoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2011 Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore…
• Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer.
  Cancer 2011 Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP
• Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.
  Cancer 2011 Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP
• Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
  American journal of hematology 2011 Ai WZ, Kohrt HE, Timmerman J, Hwang J, Hsu FJ, Czerwinski DD, Taidi B, Levy R
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R
• C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.
  American journal of clinical pathology 2010 Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS, Natkunam Y
• Left ventricular rupture due to HIV-associated T-cell lymphoma.
  Texas Heart Institute journal 2010 Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ
• Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.
  Blood 2009 Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R
• [Analysis of clinical characteristics and treatment outcome of bilateral and unilateral sudden sensorineural hearing loss].
  Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 2009 Ai W, Tong B, Liu Y, Duan M
• Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.
  International journal of cancer 2009 Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R
• ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.
  The Journal of molecular diagnostics : JMD 2007 Weinberg OK, Ai WZ, Mariappan MR, Shum C, Levy R, Arber DA
• Management of advanced stage Hodgkin lymphoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2006 Advani R, Ai WZ, Horning SJ